Skip to content

Early efficacy of leukocyte-rich and leukocyte-poor platelet-rich plasma in the treatment of knee osteoarthritis

Early efficacy of leukocyte-rich and leukocyte-poor platelet-rich plasma on knee osteoarthritis

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900028078
Enrollment
Unknown
Registered
2019-12-10
Start date
2020-01-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

Experimental group:Leukocyte-rich PRP injection
Control group:Leukocyte-poor PRP injection

Sponsors

Orthopedics department, General Hospital of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. Meet the diagnostic criteria for osteoarthritis set by the American College of Rheumatology in 2009; 3. knee pain plus radiological evidence within the past month and meet at least one of the following: age over 50 years old; morning stiffness less than 30 minutes; 4. friction during knee movement Feeling / sound X-ray evidence of knee osteoarthritis is 1, 2, or 3 (keligren lawrence radiological score): 0 (normal) no abnormalities in the joints; 1 (suspected) joint space can be narrowed and osteophytes can be present; (Mild) with obvious osteophytes, joint space can be narrowed; 3 (moderate) moderate osteophytes, joint space narrowing is more obvious, with sclerotic changes; 4 (severe) a large number of osteophytes, joint space is significantly narrowed, Severe sclerosis and obvious deformities.

Exclusion criteria

Exclusion criteria: (1) The knee joint suffers from other inflammatory pain diseases, such as rheumatism / rheumatoid disease; (2) Patients with severe cardiovascular, malignant tumor, liver disease or diabetes; (3) Those with severely damaged skin around the knee joint; (4) Patients with severe varus and valgus deformity of the knee joint; (5) Those whose knee osteoarthritis radiological score is out of range; (6) pregnant and lactating women; (7) Patients with hematological diseases, thrombocytopenia, and anemia; (8) Patients who have taken hormones or related drugs for knee arthritis in the past 2 weeks.

Design outcomes

Primary

MeasureTime frame
Cytokine concentration;

Countries

China

Contacts

Public ContactJia Zi-Shan

Department of Rehabilitation Medicine, General Hospital of the PLA

jzs1963@163.com+86 15210889919

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026